BioPhausia

PRESS RELEASE

RescueFlow® will be approved in further EU countries

BioPhausia today announces that RescueFlow®, based on the approval of the Swedish Medical Products Agency, will get marketing authorisations in Great Britain, Germany, France, The Netherlands, Denmark, Finland and Austria. The formal national registrations are expected within 1-3 months. It is later possible to apply in additional EU countries in a second wave of the registration procedure.

Erika Kjellberg Eriksson, President, BioPhausia: " The approval of RescueFlow® for marketing in these significant countries is a great success. Our position with regard to license negotiations is now strengthened".

RescueFlow® is a hypertonic saline and dextran solution, containing 7,5% saline and 6% dextran, to be administered intravenously to patients with hypovolemia and hypotension due to trauma. RescueFlow® significantly increases the blood volume within minutes after infusion.

The marketing rights for RescueFlow® for the Nordic countries have been licensed to Pharmalink Basläkemedel, Spånga, Sweden. The first deliveries are expected in June.

Uppsala, May 5, 1999

Based on its contact network and know-how, primarily in connective tissue biology, ***BioPhausia*** *is developing products for licensing to well-established pharmaceutical companies with strong marketing organizations.*

The product and project portfolio includes ***RescueFlow®,*** *a resuscitation solution,* ***Krillase®*** *for the debridement of chronic wounds (clinical phase III), and preclinical projects in the* ***tumor*** *and* ***trauma*** *treatment areas.*

For additional information, contact: Erika Kjellberg Eriksson, President, BioPhausia,
phone : +46 (0)18 –34 99 00

BioPhausia AB (publ)
AR 4, S-741 74 Uppsala, Sweden
Phone: +46 18 34 99 00
Fax: +46 18 34 94 95
E-mail: info@biophausia.se
Org.nr. 556485-0153

BioPhausia AB (publ)
AR 4, S-741 74 Uppsala, Sweden
Phone: +46 18 34 99 00
Fax: +46 18 34 94 95
E-mail: info@biophausia.se
Org.nr. 556485-0153